brand logo

Am Fam Physician. 2026;113(3):229-234

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial relationships.

Up to 2.4 million people in the United States and 254 million people worldwide have acute or chronic hepatitis B virus infection. The virus is transmitted by blood and body fluid, and approximately two-thirds of people with a chronic infection in the United States are unaware of their diagnosis. The Centers for Disease Control and Prevention recommends screening all adults at least once with triple panel testing (measurement of hepatitis B surface antigen, antibodies to hepatitis B surface antigen, and antibodies to hepatitis B core antigen) because antiviral therapy can reduce associated morbidity and mortality. Screening is also recommended during each pregnancy to reduce the risk of vertical transmission. Nonimmune patients with higher risk of exposure should be screened periodically and, if eligible, vaccinated. Only 30% of adults in the United States are vaccinated for hepatitis B. Recommendations for routine vaccination have expanded to include all children, beginning with a birth-dose vaccine; all adults 19 to 59 years of age; and adults 60 years and older at higher risk of exposure. High rates of adult and childhood vaccination, improved diagnoses of chronic hepatitis B, and broader access to care are essential to eliminate hepatitis B in the United States.

Viral hepatitides are some of the few communicable diseases with increasing mortality; hepatitis B virus (HBV) alone caused 1.1 million deaths in 2022.1 Globally, 254 million people are infected. Regions with the highest prevalence (approximately 1 in 20 people) include Africa and the Western Pacific (as defined by the World Health Organization).2 The Centers for Disease Control and Prevention (CDC) estimates that up to 2.4 million Americans have chronic HBV; in 2022, HBV caused 13,800 new cases and 1,787 deaths.3 Approximately two-thirds of US residents with chronic HBV are unaware of their infection.4 In the United States, the strategy for HBV elimination is targeted at improving this awareness because antiviral therapy can reduce the risk of hepatocellular carcinoma, progression to cirrhosis, and HBV-related death. Part I of this article summarizes new recommendations regarding screening and prevention of HBV. Part II of this article, which appears in this issue of American Family Physician, discusses updated guidelines for diagnosis and management of HBV, including surveillance for liver cancer.

Already a member/subscriber?  Log In

Subscribe

From $180
  • Immediate, unlimited access to all AFP content
  • More than 125 CME credits/year
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • Print delivery available

Article Only

$34.95
  • Immediate, unlimited access to just this article
  • CME credits
  • Print delivery available
Interested in AAFP membership?  Learn More

Continue Reading

More in AFP

More in PubMed

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.